Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galicaftor - AbbVie/Galapagos NV

Drug Profile

Galicaftor - AbbVie/Galapagos NV

Alternative Names: ABBV 2222; GLPG2222

Latest Information Update: 05 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
  • Developer AbbVie; Galapagos NV
  • Class Amides; Antifibrotics; Benzoic acids; Chromans; Cyclopropanes; Dioxolanes; Fluorinated hydrocarbons; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 05 Jul 2023 Abbvie terminates a phase II trial in Cystic fibrosis (Combination therapy, In adults) due to strategic considerations in United Kingdom, Slovakia, Hungary, Germany, Australia, New Zealand, Czech Republic, Netherlands, Belgium and USA (PO) (NCT04853368)
  • 21 Dec 2022 AbbVie completes a phase I trial for pharmacokinetics and safety study in healthy subjects in the US (PO) (NCT05538585)
  • 29 Nov 2022 AbbVie completes a phase I trial in Healthy volunteers (Combination therapy) in USA (PO) (NCT05530278)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top